FY2029 Earnings Estimate for Genelux Issued By HC Wainwright

Genelux Corporation (NASDAQ:GNLX) – Stock analysts at HC Wainwright increased their FY2029 EPS estimates for Genelux in a research note issued to investors on Friday, March 20th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of $1.66 per share for the year, up from their prior estimate of $1.61. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s FY2030 earnings at $2.58 EPS.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Thursday, January 22nd. Wall Street Zen raised Genelux from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Benchmark reduced their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research report on Friday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.40.

Genelux Stock Performance

NASDAQ:GNLX opened at $2.40 on Monday. The firm’s 50-day moving average is $2.68 and its 200-day moving average is $4.15. The company has a market cap of $107.54 million, a price-to-earnings ratio of -2.79 and a beta of 0.15. Genelux has a 52-week low of $1.99 and a 52-week high of $8.53.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.01 million for the quarter.

Insider Activity at Genelux

In other news, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $2.90, for a total transaction of $29,000.00. Following the completion of the transaction, the director directly owned 482,784 shares of the company’s stock, valued at approximately $1,400,073.60. This trade represents a 2.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GNLX. Private Management Group Inc. bought a new position in Genelux during the second quarter worth about $33,000. Jefferies Financial Group Inc. bought a new stake in shares of Genelux in the 4th quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new stake in shares of Genelux in the 4th quarter valued at approximately $52,000. Raymond James Financial Inc. raised its holdings in shares of Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after buying an additional 5,333 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Genelux in the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.